Every Form 4 that PTC Therapeutics, Inc. (PTCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTCT filings page.
PTC Therapeutics, Inc. (PTCT) chief business officer Eric Pauwels reported automatic sales of common stock to cover tax withholding from restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,789 shares of common stock at $76.95 per share. On January 7, 2026, he sold an additional 1,352 shares at $77.48 per share. Both transactions were executed under an irrevocable sell-to-cover election entered into when the RSU grants were accepted and were made to satisfy tax withholding obligations tied to the vesting of RSUs granted in January 2023 and January 2025. After these transactions, Pauwels directly beneficially owned 87,489 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. (PTCT) CEO Matthew B. Klein reported automatic sales of common stock tied to RSU vesting. On January 6, 2026, 5,149 shares of common stock were sold at $76.95 per share, and on January 7, 2026, 3,016 shares were sold at $77.48 per share. Both transactions are coded as sales and are reported as directly owned shares.
According to the footnotes, these sales were made under irrevocable "sell to cover" elections to satisfy tax withholding obligations arising from the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs. After these transactions, Klein directly beneficially owns 396,967 shares of PTC Therapeutics common stock.
PTC Therapeutics executive Golden Lee Scott, EVP & Chief Medical Officer, reported automatic sales of company stock tied to RSU vesting. On January 6, 2026, 1,340 shares of PTC Therapeutics common stock were sold at $76.95 per share in a transaction marked as a sale, leaving 93,936 shares beneficially owned directly. On January 7, 2026, a further 642 shares were sold at $77.48 per share, resulting in direct beneficial ownership of 93,294 shares.
According to the footnotes, both transactions represent shares automatically sold under an irrevocable "sell to cover" election made when the RSU grants were accepted, in order to satisfy tax withholding obligations upon vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs and 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported a series of stock option exercises and related share sales in PTCT common stock. On January 7, 2026 he exercised options for 3,376 shares at an exercise price of $38.10 per share and sold multiple small blocks of common stock at weighted average prices generally between $76.95 and $78.98 per share. Some sales on January 6–7, 2026 were automatic “sell-to-cover” transactions to satisfy tax withholding tied to vesting of restricted stock units, and other trades were carried out under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 117,659 shares of PTC Therapeutics common stock.
PTC Therapeutics officer Neil Gregory Almstead reported automatic sales of company stock tied to restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,279 shares of common stock at $76.95 per share directly and 54 shares at $76.95 held indirectly through his spouse. On January 7, 2026, he sold an additional 1,026 shares at $77.48 directly and 52 shares at $77.48 through his spouse.
According to the footnotes, all of these sales were made under irrevocable “sell to cover” elections to satisfy tax withholding obligations arising from the vesting of RSUs granted in 2023 and 2025. Following these transactions, Almstead beneficially owns 116,077 shares directly and 6,850 shares indirectly through his spouse.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead received new equity awards in the company. On January 2, 2026 he was granted 17,500 restricted stock units that vest in four equal annual installments starting January 2, 2027. He also indirectly holds 6,956 shares of common stock through his spouse, including 520 shares from this grant and 257 shares acquired under the employee stock purchase plan for the period ended December 31, 2025.
In addition, he received a stock option for 43,750 shares of common stock at an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over four years, with 25% vesting on January 2, 2027 and a further 6.25% of the original shares vesting at the end of each successive three‑month period beginning April 2, 2027. After these transactions he beneficially owns 118,382 shares directly and the 6,956 shares indirectly.
PTC Therapeutics director Jerome B. Zeldis reported new equity awards from the company. On January 2, 2026, he received 4,000 shares of common stock in the form of restricted stock units, bringing his directly held common shares to 22,500. These RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths on January 2, 2027. He has elected to defer receipt of all vested shares until the earliest of four years from grant, six months after separation of service, a change in control event, or death.
On the same date, he was also granted a stock option for 3,475 shares of common stock with an exercise price of $76.74 per share. This option vests in twelve equal monthly installments over one year starting February 2, 2026 and expires on January 1, 2036.
PTC Therapeutics director Stephanie Okey reported new equity awards. On January 2, 2026, she received 4,000 shares of common stock as restricted stock units at a grant price of $0, increasing her directly held common stock to 12,000 shares after the transaction.
The restricted stock units vest over one year, with five-twelfths of the underlying shares vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027. She was also granted a stock option for 3,475 shares of common stock at an exercise price of $76.74 per share and a grant price of $0, vesting in twelve equal monthly installments starting February 2, 2026. Following this grant, she directly holds 3,475 stock options.
PTC Therapeutics director Michael Schmertzler reported new equity awards. On January 2, 2026 he received 8,000 shares of common stock in the form of restricted stock units at a price of $0, increasing his directly held common stock to 163,266 shares. The RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027.
He was also granted a stock option for 6,950 shares of common stock with an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments starting on February 2, 2026. Both awards are reported as directly owned by Schmertzler.
PTC Therapeutics chief financial officer Pierre Gravier reported new equity awards. On January 2, 2026, he received 20,000 restricted stock units, which vest in four equal annual installments starting on January 2, 2027. His direct holdings of common stock totaled 92,449 shares after this grant, including shares previously acquired through the company’s employee stock purchase plan.
On the same date, he was also granted a stock option for 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. This option vests over four years, with 25% vesting on January 2, 2027 and an additional 6.25% of the original grant vesting at the end of each successive three-month period beginning April 2, 2027.
PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.
PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.
The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.
PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.
The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.
PTC Therapeutics (PTCT) director reports option exercises and stock sales. A board member exercised stock options on 11/24/2025 and 11/25/2025 at exercise prices of $11.23 and $18.01 per share, converting options into common stock. On the same dates, the director sold shares in multiple transactions at weighted average prices generally between the low $80 and mid $80 per share. After these transactions, the director directly owned 17,451 shares of PTC Therapeutics common stock. The filing states that the trades were carried out under a written Rule 10b5-1 trading plan adopted on March 12, 2025.
PTC Therapeutics director reports stock option exercise and sale. A board member of PTC Therapeutics, Inc. (PTCT) exercised stock options for 10,000 shares of common stock at an exercise price of $51.16 per share on 11/21/2025. On the same day, the director sold 10,000 shares of common stock at a price of $79.50 per share. After these transactions, the director beneficially owned 6,666 shares of PTCT common stock directly. The option exercise was reported as a stock option (right to buy) that was already exercisable and carries an expiration date of 01/28/2030. The filing notes that the transactions were carried out under a pre‑established Rule 10b5‑1 trading plan adopted on March 4, 2025, which is designed to allow trading under predetermined conditions.
PTC Therapeutics director reports charitable stock gift
A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.
PTC Therapeutics executive reports option exercise and share sales
The Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT) reported transactions dated 11/17/2025. The officer exercised a stock option for 2,812 shares of common stock at an exercise price of $25.69 per share, then sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, all under a Rule 10b5-1 trading plan adopted on December 5, 2024.
After these transactions, the officer beneficially owned 103,901 shares of common stock directly and 25,314 stock options with an exercise price of $25.69 expiring on 02/14/2034. The reported option grant was made on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.
PTC Therapeutics (PTCT) director reported Rule 10b5-1 trades. On 10/30/2025, the insider exercised 12,000 stock options at $38.1 per share and sold 12,000 common shares at $69.5. The filing also lists a separate sale of 3,666 shares at $69.5. After these transactions, the insider reported 6,666 shares held directly.
The trades were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025. The exercised options were currently exercisable and carry an expiration date of January 6, 2032.